Damerow, H.;                     Cheng, X.;                     von Kiedrowski, V.;                     Schirrmacher, R.;                     Wängler, B.;                     Fricker, G.;                     Wängler, C.    
        Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics 2022, 14, 2114.
    https://doi.org/10.3390/pharmaceutics14102114
    AMA Style
    
                                Damerow H,                                 Cheng X,                                 von Kiedrowski V,                                 Schirrmacher R,                                 Wängler B,                                 Fricker G,                                 Wängler C.        
                Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics. 2022; 14(10):2114.
        https://doi.org/10.3390/pharmaceutics14102114
    
    Chicago/Turabian Style
    
                                Damerow, Helen,                                 Xia Cheng,                                 Valeska von Kiedrowski,                                 Ralf Schirrmacher,                                 Björn Wängler,                                 Gert Fricker,                                 and Carmen Wängler.        
                2022. "Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?" Pharmaceutics 14, no. 10: 2114.
        https://doi.org/10.3390/pharmaceutics14102114
    
    APA Style
    
                                Damerow, H.,                                 Cheng, X.,                                 von Kiedrowski, V.,                                 Schirrmacher, R.,                                 Wängler, B.,                                 Fricker, G.,                                 & Wängler, C.        
        
        (2022). Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics, 14(10), 2114.
        https://doi.org/10.3390/pharmaceutics14102114